Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.043
Sell
RSI(14)
32.072
Neutral
STOCH(KDJ)(9,3,3)
5.476
Oversold
ATR(14)
0.089
High Vlolatility
CCI(14)
-142.432
Sell
Williams %R
98.864
Oversold
TRIX(12,20)
-0.525
Sell
StochRSI(14)
0.000
Sell
Search
Geron Corp
GERNAdd to Watchlist
1.290USD
-0.110-7.86%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
827.56MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Geron Corp
Currency: USD Updated: 2026-05-15Key Insights
Geron Corp's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 79 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 3.40.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Geron Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Geron Corp Highlights
StrengthsRisks
Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 77486.92% year-on-year.
Undervalued
The company’s latest PE is -12.78, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 493.34M shares, decreasing 33.85% quarter-over-quarter.
Held by Invesco
Star Investor Invesco holds 853.06K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.39.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
3.400
Target Price
+142.86%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of Geron Corp is 6.89, ranking 167 out of 382 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 51.84M, representing a year-over-year increase of 30.89%, while its net profit experienced a year-over-year increase of 81.64%.
Score
Financials
5.37
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.50
Operational Efficiency
7.62
Growth Potential
6.81
Shareholder Returns
7.15
Geron Corp's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of Geron Corp is 7.00, ranking 179 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -12.78, which is -100.00% below the recent high of 0.00 and -28.14% above the recent low of -16.38.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 79/382
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of Geron Corp is 7.43, ranking 296 out of 382 in the Biotechnology & Medical Research industry. The average price target is 4.00, with a high of 5.00 and a low of 1.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
3.400
Target Price
+142.86%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
Geron Corp
GERN
6
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Beigene Ltd
ONC
26
Ionis Pharmaceuticals Inc
IONS
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of Geron Corp is 6.35, ranking 254 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.58 and the support level at 1.14, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
1.378
Sell
MA10
1.454
Sell
MA20
1.491
Sell
MA50
1.565
Sell
MA100
1.525
Sell
MA200
1.406
Sell
Institutional Confidence
Currency: USD Updated: 2026-05-15The current institutional shareholding score of Geron Corp is 7.00, ranking 83 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 76.90%, representing a quarter-over-quarter decrease of 5.14%. The largest institutional shareholder is James Simons, holding a total of 1.80M shares, representing 0.28% of shares outstanding, with 68.10% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Geron Corp is 5.19, ranking 50 out of 382 in the Biotechnology & Medical Research industry. The company's beta value is 0.66. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.63
VaR
+6.47%
240-Day Maximum Drawdown
+33.95%
240-Day Volatility
+68.64%
Return
Best Daily Return
60 days
+11.41%
120 days
+12.41%
5 years
+92.00%
Worst Daily Return
60 days
-11.79%
120 days
-11.79%
5 years
-32.07%
Sharpe Ratio
60 days
-1.91
120 days
+0.88
5 years
+0.38
Risk Assessment
Maximum Drawdown
240 days
+33.95%
3 years
+100.00%
5 years
+100.00%
Return-to-Drawdown Ratio
240 days
-0.29
3 years
-0.20
5 years
+0.01
Skewness
240 days
+0.43
3 years
+6.82
5 years
+4.94
Volatility
Realised Volatility
240 days
+68.64%
5 years
--
Standardised True Range
240 days
+6.83%
5 years
+10.93%
Downside Risk-Adjusted Return
120 days
+143.89%
240 days
+143.89%
Maximum Daily Upside Volatility
60 days
+54.05%
Maximum Daily Downside Volatility
60 days
+60.39%
Liquidity
Average Turnover Rate
60 days
+2.99%
120 days
+2.30%
5 years
--
Turnover Deviation
20 days
+42.03%
60 days
+61.46%
120 days
+24.04%
Peer Comparison
Biotechnology & Medical Research
Geron Corp
GERN
6.75 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
